Furmonertinib Clinical Trials (2026): 56 Studies for Non-small Cell Lung Cancer & NSCLC
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
56 Furmonertinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 29 indications (including Non-small Cell Lung Cancer & NSCLC) and 10,289 total planned enrollment. 4 Phase 3 Furmonertinib trials and 37 Phase 2 are listed. 33 Furmonertinib clinical trials are actively recruiting. Most recent activity: NCT06585644 (Jun 2030).
Furmonertinib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | withdrawn | not yet recruiting | unknown | Total |
|---|---|---|---|---|---|---|---|
| P1 | 1 | 2 | 1 | 4 | |||
| P1/P2 | 4 | 1 | 5 | ||||
| P2 | 11 | 1 | 3 | 10 | 12 | 37 | |
| P3 | 3 | 1 | 4 | ||||
| N/A | 3 | 1 | 1 | 1 | 6 |
Recruiting Furmonertinib clinical trials (33)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06585644 | A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC | P2 | Lung Cancer (NSCLC) | 44 | Oct 2024 |
| NCT07229599 | A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer | P1/P2 | Advanced Lung Cancer | 300 | May 2025 |
| NCT04853342 | FORWARDTo Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy | P3 | Non-small Cell Lung Carcinoma | 318 | Jun 2021 |
| NCT07304739 | SRTFurmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases | P2 | Non Small Cell Lung Cancer | 30 | Dec 2025 |
| NCT06970639 | EGFRA Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases | P3 | NSCLC Patients With Brain Metastasis | 380 | Sep 2024 |
| NCT07348965 | Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis | N/A | NSCLC (Advanced Non-small Cell Lung Cancer) | 42 | Mar 2026 |
| NCT07365410 | Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study | P2 | Non-small Cell Lung Cancer (NSCLC) | 60 | Jan 2026 |
| NCT06674343 | Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations | P3 | Advanced or Metastatic Non-small Cell Lung Cancer | 144 | Jul 2024 |
| NCT05503667 | Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma | P2 | Lung Adenocarcinoma Stage III | 96 | Feb 2022 |
| NCT06868732 | Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC | P1 | Advanced Non-small Cell Lung Cancer | 288 | Apr 2025 |
| NCT06945705 | A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis | P2 | NSCLC | 146 | Apr 2025 |
| NCT07517640 | Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial | P2 | Non-small Cell Lung Cancer | 45 | Apr 2026 |
| NCT07087223 | Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure | P1/P2 | Non Small Cell Lung Cancer NSCLC | 42 | Apr 2025 |
| NCT05334277 | FOCUS-CFurmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA | P2 | Non-small Cell Lung Cancer | 280 | May 2022 |
| NCT06452433 | Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer. | P2 | Non-small Cell Lung Cancer | 91 | Jun 2024 |
| NCT06728865 | Better BrainEvaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study | P2 | Non-small Cell Lung Cancer (NSCLC) | 70 | Sep 2024 |
| NCT07482605 | Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion | P2 | Lung Cancer (NSCLC) | 63 | Mar 2026 |
| NCT06962865 | A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC | P2 | Non-Small Cell Lung Cancer | 80 | Jun 2025 |
| NCT06652048 | High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI | P2 | Non-Small Cell Lung Cancer | 60 | Oct 2024 |
| NCT06483672 | LungBrain001Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases | P2 | Adenocarcinoma of Lung Metastatic to Brain | 27 | Jul 2024 |
| NCT07169994 | A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | P1/P2 | Advanced Solid Tumors | 414 | Sep 2025 |
| NCT07193160 | Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy | P2 | NSCLC (Non-small Cell Lung Cancer) | 45 | Nov 2025 |
| NCT06192849 | To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy | P2 | Non Small Cell Lung Cancer | 20 | Dec 2023 |
| NCT06319950 | High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases | P2 | Lung Cancer, Nonsmall Cell | 255 | Apr 2024 |
| NCT06185400 | RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations | P2 | Non Small Cell Lung Cancer | 108 | Feb 2024 |
| NCT06117644 | The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC | — | Non Small Cell Lung Cancer | 30 | Nov 2023 |
| NCT06394674 | High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib | P2 | Non-Small Cell Lung Cancer | 84 | May 2024 |
| NCT05994131 | IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC | P1/P2 | NSCLC | 110 | Jul 2023 |
| NCT05445310 | Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer | P2 | Non-small Cell Lung Cancer | 114 | Aug 2022 |
| NCT06537297 | Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases | P2 | Non-small Cell Lung Cancer | 30 | Sep 2024 |
| NCT06604689 | AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases | — | NSCLC (Advanced Non-small Cell Lung Cancer) | 800 | Sep 2024 |
| NCT06643000 | Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis | N/A | Non-small Cell Lung Cancer | 60 | Dec 2024 |
| NCT05379803 | CNSHigh-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases | P2 | Non-Small Cell Lung Cancer | 40 | May 2022 |
Furmonertinib clinical trials by indication
Non-small Cell Lung Cancer (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07517640 | — | P2 | not yet recruiting | Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial |
| NCT05334277 | FOCUS-C | P2 | recruiting | Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA |
| NCT06452433 | — | P2 | not yet recruiting | Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer. |
| NCT05445310 | — | P2 | recruiting | Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer |
| NCT06537297 | — | P2 | not yet recruiting | Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases |
| NCT05430802 | FORESEE | P2 | unknown | Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE) |
| NCT05548348 | — | P2 | unknown | First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation |
| NCT06643000 | — | N/A | recruiting | Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis |
| + 1 more, see All trials below. | ||||
NSCLC (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06945705 | — | P2 | recruiting | A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis |
| NCT05466149 | — | P2 | active not recruiting | Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion |
| NCT05994131 | — | P1/P2 | recruiting | IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC |
| NCT04858958 | FAVOUR | P1 | active not recruiting | Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation |
| NCT06339242 | — | P2 | unknown | A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis |
| NCT05165355 | ATHEM | P2 | unknown | Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma |
| NCT04958967 | — | P1 | withdrawn | Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation |
Non Small Cell Lung Cancer (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07304739 | SRT | P2 | recruiting | Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases |
| NCT06192849 | — | P2 | recruiting | To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy |
| NCT06185400 | — | P2 | not yet recruiting | RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations |
| NCT06117644 | — | N/A | not yet recruiting | The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC |
| NCT05813522 | — | P2 | unknown | Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC |
| NCT05847764 | — | P2 | unknown | Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations |
Non-Small Cell Lung Cancer (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06962865 | — | P2 | recruiting | A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC |
| NCT06652048 | — | P2 | recruiting | High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI |
| NCT06394674 | — | P2 | recruiting | High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib |
| NCT05987826 | — | P2 | unknown | Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC |
| NCT05379803 | CNS | P2 | recruiting | High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases |
Lung Cancer (NSCLC) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06585644 | — | P2 | not yet recruiting | A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC |
| NCT07482605 | — | P2 | not yet recruiting | Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion |
NSCLC (Advanced Non-small Cell Lung Cancer) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07348965 | — | N/A | recruiting | Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis |
| NCT06604689 | — | N/A | recruiting | AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases |
Non-small Cell Lung Cancer (NSCLC) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07365410 | — | P2 | not yet recruiting | Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study |
| NCT06728865 | Better Brain | P2 | recruiting | Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study |
Non-Small-Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05255406 | FUTURE | P2 | unknown | Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE) |
| NCT04895930 | FOCUS-A | P2 | unknown | Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC |
NSCLC (Non-small Cell Lung Cancer) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07193160 | — | P2 | not yet recruiting | Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy |
Advanced Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07169994 | — | P1/P2 | recruiting | A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors |
Advanced Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07229599 | — | P1/P2 | recruiting | A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer |
Non Small Cell Lung Cancer NSCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07087223 | — | P1/P2 | recruiting | Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure |
Advanced Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06868732 | — | P1 | recruiting | Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC |
NSCLC Patients With Brain Metastasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06970639 | EGFR | P3 | recruiting | A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases |
Adenocarcinoma of Lung Metastatic to Brain (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06483672 | LungBrain001 | P2 | not yet recruiting | Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases |
Advanced or Metastatic Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06674343 | — | P3 | recruiting | Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations |
Lung Cancer, Nonsmall Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06319950 | — | P2 | not yet recruiting | High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases |
Non-small Cell Lung Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06812871 | — | P2 | completed | High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis |
Metastatic Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05607550 | NSCLC | P3 | active not recruiting | Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) |
Furmonertinib (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05465343 | — | P2 | completed | Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE) |
Non-Small Cell Lung Cancer (NSCLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05364073 | NSCLC | P1 | active not recruiting | Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations |
Lung Adenocarcinoma Stage III (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05503667 | — | P2 | recruiting | Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma |
EGF-R Positive Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06352502 | — | N/A | unknown | An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis |
Adenocarcinoma of Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05079022 | — | P1/P2 | unknown | ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas |
Multiple Primary Lung Cancers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04982900 | TERMGGO | P2 | unknown | Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities |
Lung Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04965831 | N1-N2 | P2 | unknown | Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT) |
Non-small Cell Lung Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04853342 | FORWARD | P3 | recruiting | To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy |
Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04671303 | — | P2 | completed | To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer |
Third-generation TKI (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06613633 | — | N/A | completed | Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC |
Furmonertinib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| FORWARD | NCT04853342 | P3 | recruiting | Non-small Cell Lung Carcinoma | 318 | — |
| EGFR | NCT06970639 | P3 | recruiting | NSCLC Patients With Brain Metastasis | 380 | — |
| NSCLC | NCT05607550 | P3 | active not recruiting | Metastatic Non-Small Cell Lung Cancer | 398 | — |
| SRT | NCT07304739 | P2 | recruiting | Non Small Cell Lung Cancer | 30 | — |
| FOCUS-C | NCT05334277 | P2 | recruiting | Non-small Cell Lung Cancer | 280 | — |
| Better Brain | NCT06728865 | P2 | recruiting | Non-small Cell Lung Cancer (NSCLC) | 70 | — |
| LungBrain001 | NCT06483672 | P2 | not yet recruiting | Adenocarcinoma of Lung Metastatic to Brain | 27 | — |
| N1-N2 | NCT04965831 | P2 | unknown | Lung Adenocarcinoma | 40 | — |
| FORESEE | NCT05430802 | P2 | unknown | Non-small Cell Lung Cancer | 40 | — |
| CNS | NCT05379803 | P2 | recruiting | Non-Small Cell Lung Cancer | 40 | — |
| ATHEM | NCT05165355 | P2 | unknown | NSCLC | 90 | — |
| FUTURE | NCT05255406 | P2 | unknown | Non-Small-Cell Lung Cancer | 62 | — |
| FOCUS-A | NCT04895930 | P2 | unknown | Non-Small-Cell Lung Cancer | 40 | — |
| TERMGGO | NCT04982900 | P2 | unknown | Multiple Primary Lung Cancers | 138 | — |
Terminated and withdrawn Furmonertinib trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT04958967withdrawnPhase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation
All Furmonertinib trials (56)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06585644 | A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC | P2 | not yet recruiting | 44 | Shanghai Pulmonary Hospital, Shanghai, China | Oct 2024 | |
| NCT07229599 | A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer | P1/P2 | recruiting | 300 | Minghui Pharmaceutical (Hangzhou) Ltd | May 2025 | |
| NCT04853342 | FORWARD | To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy | P3 | recruiting | 318 | Allist Pharmaceuticals, Inc. | Jun 2021 |
| NCT07304739 | SRT | Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases | P2 | recruiting | 30 | Tianjin Medical University Cancer Institute and Hospital | Dec 2025 |
| NCT06970639 | EGFR | A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases | P3 | recruiting | 380 | Allist Pharmaceuticals, Inc. | Sep 2024 |
| NCT07348965 | Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis | N/A | recruiting | 42 | Guangzhou University of Traditional Chinese Medicine | Mar 2026 | |
| NCT07365410 | Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study | P2 | not yet recruiting | 60 | Tianjin Medical University Cancer Institute and Hospital | Jan 2026 | |
| NCT06674343 | Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations | P3 | recruiting | 144 | Peking Union Medical College Hospital | Jul 2024 | |
| NCT05503667 | Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma | P2 | recruiting | 96 | Shanghai Pulmonary Hospital, Shanghai, China | Feb 2022 | |
| NCT06868732 | Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC | P1 | recruiting | 288 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Apr 2025 | |
| NCT06945705 | A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis | P2 | recruiting | 146 | Henan Cancer Hospital | Apr 2025 | |
| NCT07517640 | Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial | P2 | not yet recruiting | 45 | Shanghai Pulmonary Hospital, Shanghai, China | Apr 2026 | |
| NCT07087223 | Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure | P1/P2 | recruiting | 42 | Peking University Cancer Hospital & Institute | Apr 2025 | |
| NCT05334277 | FOCUS-C | Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA | P2 | recruiting | 280 | Sun Yat-sen University | May 2022 |
| NCT05607550 | NSCLC | Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) | P3 | active not recruiting | 398 | ArriVent BioPharma, Inc. | Jun 2023 |
| NCT06452433 | Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer. | P2 | not yet recruiting | 91 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Jun 2024 | |
| NCT06728865 | Better Brain | Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study | P2 | recruiting | 70 | Li-kun Chen | Sep 2024 |
| NCT07482605 | Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion | P2 | not yet recruiting | 63 | Jiangmen Central Hospital | Mar 2026 | |
| NCT06962865 | A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC | P2 | recruiting | 80 | RemeGen Co., Ltd. | Jun 2025 | |
| NCT06652048 | High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI | P2 | recruiting | 60 | Jialei Wang | Oct 2024 | |
| NCT06483672 | LungBrain001 | Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases | P2 | not yet recruiting | 27 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Jul 2024 |
| NCT07169994 | A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | P1/P2 | recruiting | 414 | MediLink Therapeutics (Suzhou) Co., Ltd. | Sep 2025 | |
| NCT07193160 | Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy | P2 | not yet recruiting | 45 | Fudan University | Nov 2025 | |
| NCT06192849 | To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy | P2 | recruiting | 20 | Juan LI, MD | Dec 2023 | |
| NCT05466149 | Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion | P2 | active not recruiting | 100 | Allist Pharmaceuticals, Inc. | Sep 2022 | |
| NCT05364073 | NSCLC | Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations | P1 | active not recruiting | 160 | ArriVent BioPharma, Inc. | Jun 2022 |
| NCT06319950 | High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases | P2 | not yet recruiting | 255 | Taizhou Hospital | Apr 2024 | |
| NCT06185400 | RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations | P2 | not yet recruiting | 108 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Feb 2024 | |
| NCT06117644 | The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC | — | not yet recruiting | 30 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Nov 2023 | |
| NCT06394674 | High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib | P2 | recruiting | 84 | Changhai Hospital | May 2024 | |
| NCT05994131 | IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC | P1/P2 | recruiting | 110 | InxMed (Shanghai) Co., Ltd. | Jul 2023 | |
| NCT05445310 | Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer | P2 | recruiting | 114 | Peking Union Medical College Hospital | Aug 2022 | |
| NCT04965831 | N1-N2 | Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT) | P2 | unknown | 40 | Tianjin Medical University Cancer Institute and Hospital | Aug 2021 |
| NCT06537297 | Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases | P2 | not yet recruiting | 30 | Hunan Province Tumor Hospital | Sep 2024 | |
| NCT06812871 | High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis | P2 | completed | 46 | Sun Yat-sen University | Jan 2024 | |
| NCT05430802 | FORESEE | Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE) | P2 | unknown | 40 | Tang-Du Hospital | Feb 2022 |
| NCT04858958 | FAVOUR | Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation | P1 | active not recruiting | 30 | Allist Pharmaceuticals, Inc. | Aug 2020 |
| NCT06613633 | Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC | — | completed | 4,000 | Fudan University | Sep 2018 | |
| NCT06339242 | A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis | P2 | unknown | 30 | Jiangsu Province Nanjing Brain Hospital | Jan 2024 | |
| NCT05987826 | Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC | P2 | unknown | 40 | Shanghai Zhongshan Hospital | Aug 2023 | |
| NCT05465343 | Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE) | P2 | completed | 24 | Peking Union Medical College | Jul 2022 | |
| NCT05548348 | First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation | P2 | unknown | 30 | Chongqing University Cancer Hospital | Sep 2022 | |
| NCT06604689 | AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases | — | recruiting | 800 | Fudan University | Sep 2024 | |
| NCT05813522 | Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC | P2 | unknown | 30 | First Affiliated Hospital of Zhejiang University | Apr 2022 | |
| NCT05847764 | Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations | P2 | unknown | 95 | Sun Yat-sen University | May 2023 | |
| NCT06643000 | Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis | N/A | recruiting | 60 | Henan Cancer Hospital | Dec 2024 | |
| NCT05379803 | CNS | High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases | P2 | recruiting | 40 | Hunan Province Tumor Hospital | May 2022 |
| NCT05165355 | ATHEM | Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma | P2 | unknown | 90 | Tongji University | Dec 2021 |
| NCT05255406 | FUTURE | Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE) | P2 | unknown | 62 | Fudan University | Dec 2021 |
| NCT06352502 | An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis | — | unknown | 30 | Tang-Du Hospital | Jan 2022 | |
| NCT05079022 | ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas | P1/P2 | unknown | 50 | Peking University People's Hospital | Oct 2021 | |
| NCT04970693 | A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression | P2 | unknown | 64 | Sun Yat-sen University | Jun 2021 | |
| NCT04895930 | FOCUS-A | Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC | P2 | unknown | 40 | Shanghai Chest Hospital | Oct 2021 |
| NCT04671303 | To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer | P2 | completed | 36 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Jan 2021 | |
| NCT04982900 | TERMGGO | Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities | P2 | unknown | 138 | Ruijin Hospital | Oct 2021 |
| NCT04958967 | Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation | P1 | withdrawn | 0 | Allist Pharmaceuticals, Inc. | Oct 2021 |
Furmonertinib clinical trials: frequently asked questions
- How many Furmonertinib clinical trials are there?
- 56 Furmonertinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 22 are actively recruiting participants. 4 are marked completed.
- Are Furmonertinib clinical trials recruiting in 2026?
- Yes — 22 Furmonertinib trials are actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is Furmonertinib being studied for?
- Furmonertinib is being studied for Non-small Cell Lung Cancer, NSCLC, Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Brain Metastases and 53 more. The trials are grouped by indication on this page.
- What phase is Furmonertinib in?
- Furmonertinib clinical trials span 4 Phase 3, 37 Phase 2, 4 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Furmonertinib clinical trials?
- The lead sponsor across the most Furmonertinib trials is Allist Pharmaceuticals, Inc., with 33 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Furmonertinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: